نتائج البحث - "Daniel J. Wallace"

1

POS0697 SAFETY OF BELIMUMAB IN ADULT PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A LARGE INTEGRATED SAFETY ANALYSIS OF CONTROLLED CLINICAL TRIAL DATA

المؤلفون: F. Zhang, M. Daniels, Anne E. Hammer, Toshiya Atsumi, P. Meizlik, Daniel J. Wallace, David M. Roth, H. Quasny, Andreas Schwarting

المصدر: Annals of the Rheumatic Diseases. 80:596.2-597

مصطلحات موضوعية: medicine.medical_specialty, Adult patients, business.industry, Incidence (epidemiology), Immunology, Placebo, Belimumab, General Biochemistry, Genetics and Molecular Biology, Clinical trial, Safety profile, Rheumatology, Internal medicine, Immunology and Allergy, Medicine, business, Adverse effect, Depression (differential diagnoses), medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::e50e9ef7f72af85e7d119e3c89546d8b
https://doi.org/10.1136/annrheumdis-2021-eular.2373

Find this article in full text from ProQuest

2

Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

المؤلفون: Michelle A. Petri, Kenneth C. Kalunian, David A. Isenberg, M Morgan-Cox, N Iikuni, Yoshiya Tanaka, Murray B. Urowitz, Robert W Hoffman, M. Silk, Daniel J. Wallace

المصدر: Annals of the Rheumatic Diseases. 75:323-331

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::dfb01d8f1d93c0378c5a0c84be38a730
https://doi.org/10.1136/annrheumdis-2015-207653

Find this article in full text from ProQuest

3

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

المؤلفون: Daniel J. Wallace, Vibeke Strand, Frédéric Houssiau, B. Kilgallen, Michelle Petri, Caroline Gordon, Lexy Kelley, Marilyn C. Pike, Kenneth C. Kalunian, S. Bongardt, Anna Barry

المساهمون: UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, UCL - (SLuc) Service de rhumatologie

المصدر: Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases, Vol. 73, no. 1, p. 183-190 (2013)

مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Immunology, Treatment outcome, Placebo, Antibodies, Monoclonal, Humanized, Severity of Illness Index, Systemic Lupus Erythematosus, General Biochemistry, Genetics and Molecular Biology, Double blind, Placebos, Rheumatology, Double-Blind Method, immune system diseases, Internal medicine, Severity of illness, medicine, Immunology and Allergy, Humans, Lupus Erythematosus, Systemic, In patient, skin and connective tissue diseases, B-Lymphocytes, B cells, business.industry, Dosing regimen, Middle Aged, Clinical and Epidemiological Research, medicine.disease, Connective tissue disease, 3. Good health, Surgery, Treatment, Treatment Outcome, Female, business, Epratuzumab, Immunosuppressive Agents, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c41350b368609a2618146fd1a58509b
https://pubmed.ncbi.nlm.nih.gov/23313811

Find this article in full text from ProQuest

4

Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study

المؤلفون: Barbara White, Gabriel Robbie, Bahija Jallal, Daniel J. Wallace, Chenxiong Le, Nancy J. Olsen, Michelle Petri, Kyriakos A. Kirou, Wendy I. White, Laura Richman, Yihong Yao, Robert Levin, Seth Mark Berney, Joan T. Merrill, Vishala Chindalore

المصدر: Annals of the rheumatic diseases. 70(11)

مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Immunology, Placebo, Antibodies, Monoclonal, Humanized, Gastroenterology, Severity of Illness Index, General Biochemistry, Genetics and Molecular Biology, Young Adult, Rheumatology, Double-Blind Method, Internal medicine, Immunopathology, medicine, Immunology and Allergy, Humans, Lupus Erythematosus, Systemic, RNA, Messenger, Adverse effect, Interferon alfa, Aged, Aged, 80 and over, Lupus erythematosus, Dose-Response Relationship, Drug, business.industry, Antibodies, Monoclonal, Interferon-alpha, Middle Aged, medicine.disease, Connective tissue disease, Treatment Outcome, Gene Expression Regulation, Pharmacodynamics, Injections, Intravenous, Interferon Type I, Female, Sifalimumab, business, Immunosuppressive Agents, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3420ba2b5b00be49820d5c32019d4899
https://pubmed.ncbi.nlm.nih.gov/21798883

Find this article in full text from ProQuest

5

OP0185 Significant Clinical Improvement and Reduction of Severe Flares Following Administration of an IL-6 Monoclonal Antibody in Systemic Lupus Erythematosus (SLE) Subjects with High Disease Activity

المؤلفون: Joan T. Merrill, I. Szombati, Jared Christensen, Vibeke Strand, Serghei Popa, Annette Diehl, Joseph Wajdula, Cheryl Li, Jean Elizabeth Beebe, Paul J. Healey, Josef S Smolen, M. Petri, Peter E. Lipsky, Michael S. Vincent, Daniel J. Wallace, Sudhakar Sridharan

المصدر: Annals of the Rheumatic Diseases. 74:141.2-142

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::1f0c4982c370997561efa0a099cff912
https://doi.org/10.1136/annrheumdis-2015-eular.1428

Find this article in full text from ProQuest

6

OP0184 Efficacy and Safety of Tabalumab in Patients with Systemic Lupus Erythematosus (SLE): Results from 2 Phase 3, 52-Week, Multicenter, Randomized, Placebo-Controlled Trials: Table 1

المؤلفون: M. Silk, Thomas Dörner, M Morgan-Cox, David A. Isenberg, Matthew D. Linnik, Daniel J. Wallace, Joan T. Merrill, Robert W Hoffman, N Iikuni, C. Dickson, Melissa Veenhuizen

المصدر: Annals of the Rheumatic Diseases. 74:141.1-141

مصطلحات موضوعية: medicine.medical_specialty, Standard of care, business.industry, Immunology, Placebo, Loading dose, General Biochemistry, Genetics and Molecular Biology, Tabalumab, Safety profile, Rheumatology, Internal medicine, Clinical endpoint, medicine, Immunology and Allergy, In patient, Cns disease, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::eae3d604525a5db88e1885ef2836d706
https://doi.org/10.1136/annrheumdis-2015-eular.1195

Find this article in full text from ProQuest

7

THU0023 Correlation of Laboratory and Clinical Parameters with British Isles Lupus Assessment Group Response in an Open-Label Extension Study of Epratuzumab in Systemic Lupus Erythematosus

المؤلفون: W. Koetse, Vibeke Strand, S. Bongardt, Caroline Gordon, Michelle Petri, R.A. Furie, C. Galateanu, Daniel J. Wallace

المصدر: Annals of the Rheumatic Diseases. 73:184.1-184

مصطلحات موضوعية: medicine.medical_specialty, Systemic lupus erythematosus, business.industry, Extension study, Immunology, Placebo, medicine.disease, General Biochemistry, Genetics and Molecular Biology, Rheumatology, Concomitant, Internal medicine, Clinical endpoint, Immunology and Allergy, Medicine, In patient, Open label, business, Epratuzumab, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::29dd0571a593041b6a85a3d7032057b4
https://doi.org/10.1136/annrheumdis-2014-eular.1854

Find this article in full text from ProQuest

8

AB0496 Corticosteroid Use across 52 Weeks of Belimumab Therapy in SLE Patients with High Disease Activity: Combined Analyses from the BLISS Trials

المؤلفون: T. Tang, Daniel J. Wallace, R. van Vollenhoven, A. Thompson, C. Molta, David M. Roth, Anne E. Hammer, M. Petri

المصدر: Annals of the Rheumatic Diseases. 73:971.1-971

مصطلحات موضوعية: Belimumab therapy, medicine.medical_specialty, business.industry, Cumulative dose, Immunology, Placebo, Belimumab, General Biochemistry, Genetics and Molecular Biology, Disease activity, Rheumatology, Prednisone, Internal medicine, Physical therapy, Clinical endpoint, Immunology and Allergy, Medicine, Corticosteroid use, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::cbef955a7271ddc0c486cb168c7a9289
https://doi.org/10.1136/annrheumdis-2014-eular.4969

Find this article in full text from ProQuest

9

AB0633 Epratuzumab-treated SLE patients report improvements in health-related quality of life: Interim results from a us open-label extension study

المؤلفون: B. Kilgallen, Daniel J. Wallace, Vibeke Strand, Kathryn Hobbs, Kenneth C. Kalunian, William A. Wegener, E. Nikaï

المصدر: Annals of the Rheumatic Diseases. 71:675.1-675

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::be530679c0707a1d7135d0d92fe29e5d
https://doi.org/10.1136/annrheumdis-2012-eular.633

Find this article in full text from ProQuest

10

THU0272 Epratuzumab Maintains Improvements in Disease Activity for Over 2 Years in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from an Open-Label Long-Term Extension Study (Sl0008)

المؤلفون: Daniel J. Wallace, B. Kilgallen, Kenneth C. Kalunian, Frédéric Houssiau, Vibeke Strand, Caroline Gordon, Michelle Petri, S. Bongardt, M. Clowse

المصدر: Annals of the Rheumatic Diseases. 72:A257.2-A257

مصطلحات موضوعية: Moderate to severe, medicine.medical_specialty, business.industry, Extension study, Immunology, BLINDED TREATMENT, Placebo, General Biochemistry, Genetics and Molecular Biology, Disease activity, Rheumatology, Internal medicine, Immunology and Allergy, Medicine, In patient, Open label, business, Epratuzumab, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::e56e17c044b36c011b1ba6c6b5932e32
https://doi.org/10.1136/annrheumdis-2013-eular.800

Find this article in full text from ProQuest

تنقيح النتائج